Bile acid-activated receptors in the treatment of dyslipidemia and related disorders

Progress in Lipid Research
Stefano FiorucciAndrea Mencarelli

Abstract

Dyslipidemia is a metabolic disorder that constitutes a major risk factor for cardiovascular diseases and stroke and is often associated with diabetes mellitus and atherosclerosis. In recent years a number of ligand-activated receptors have been found to exert a role in integrating essential steps of lipid and glucose metabolism. Bile acid-activated receptors are a defined subset of nuclear and G-protein coupled receptors mainly expressed in entero-hepatic tissues for which bile acids function as signaling molecules. Primary bile acids (chenodeoxycholic acid and cholic acid) are physiological ligands/activators of farnesoid-X-receptor (FXR), pregnane-X-receptor (PXR) and constitutive androstane receptor (CAR), while litocholic acid is a ligand for the Vitamin D receptor (VDR) and the G-protein coupled receptor TGR5. Despite FXR demonstrates a high selectivity for bile acids, PXR and CAR are relatively promiscuous receptors integrating lipid homeostasis with xenobiotic metabolism. FXR, PXR, CAR and TGR exert synergistic activities in regulating lipid and glucose homeostasis and energy expenditure and liver and peripheral insulin sensitivity. Ligands for these receptors hold promise in the treatment of dyslipidemic conditions as ...Continue Reading

References

Mar 1, 1978·British Journal of Clinical Pharmacology·M C BatesonI A Bouchier
Sep 1, 1974·Tubercle·A M KhogaliJ H Ramsay
Nov 10, 1998·Circulation·B StaelsJ C Fruchart
May 21, 1999·Science·M MakishimaB Shan
May 21, 1999·Science·D J ParksJ M Lehmann
Jun 9, 1999·Molecular Cell·H WangB M Forman
Sep 23, 2000·Nature·A J Lusis
Mar 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·J L StaudingerS A Kliewer
Mar 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·W XieR M Evans
Jul 24, 2001·The Journal of Biological Chemistry·I DussaultB M Forman
Jan 15, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·Jon H MiyakeRoger A Davis
Mar 20, 2002·The Journal of Biological Chemistry·Joyce J RepaDavid J Mangelsdorf
May 23, 2002·Science·Makoto MakishimaDavid J Mangelsdorf
Jun 14, 2002·Developmental Cell·Li WangDavid D Moore
Jul 3, 2002·The Journal of Clinical Investigation·Clive R PullingerJohn P Kane
Nov 7, 2002·Biochemical and Biophysical Research Communications·Takaharu MaruyamaKenichi Tanaka
Nov 8, 2002·The Journal of Biological Chemistry·Gilles LambertChristopher J Sinal
Jan 14, 2003·The Journal of Biological Chemistry·Yuji KawamataMasahiko Fujino
Mar 28, 2003·The Journal of Biological Chemistry·Andrew M AnisfeldPeter A Edwards
May 6, 2003·Nature Genetics·Marianne AbifadelCatherine Boileau
Aug 2, 2003·Gastroenterology·Thierry ClaudelBart Staels
Mar 30, 2004·Diabetes·Daniel Duran-SandovalBart Staels
May 18, 2004·The Journal of Clinical Investigation·Mitsuhiro WatanabeJohan Auwerx
Jun 5, 2004·Biochemical and Biophysical Research Communications·Jamila Fruchart-NajibJean-Charles Fruchart
Jun 30, 2004·International Journal of Clinical Pharmacology and Therapeutics·D LütjohannC Reichel
Jul 1, 2004·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Kenneth BachmannLidia Sambucetti
Aug 28, 2004·American Journal of Physiology. Gastrointestinal and Liver Physiology·Tiangang Li, John Y L Chiang

❮ Previous
Next ❯

Citations

Feb 1, 2011·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Barbara RengaStefano Fiorucci
Jan 7, 2014·Journal of Medicinal Chemistry·Claudio D'AmoreVittorio Limongelli
Apr 28, 2010·Seminars in Liver Disease·Carol J SorokaJames L Boyer
Jul 15, 2011·Experimental Diabetes Research·Xiaosong ChenWendong Huang
Jun 12, 2013·The Journal of Endocrinology·Elena ManeschiMario Maggi
Mar 24, 2011·Future Medicinal Chemistry·Ramona SteriManfred Schubert-Zsilavecz
May 11, 2012·Future Medicinal Chemistry·Stefano FiorucciAngela Zampella
Jan 7, 2014·European Journal of Medicinal Chemistry·Valentina SepeStefano Fiorucci
May 21, 2014·Best Practice & Research. Clinical Endocrinology & Metabolism·Marcin BarylskiGiuseppe Montalto
Jun 20, 2013·Cholesterol·Anouar Hafiane, Jacques Genest
Jul 18, 2015·Expert Opinion on Therapeutic Patents·Valentina SepeAngela Zampella
Jan 22, 2013·Drug Metabolism Reviews·Tiangang Li, John Y L Chiang
Sep 20, 2011·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·A MencarelliS Fiorucci
Jun 24, 2010·Biochimica Et Biophysica Acta·Tadeja RezenKatalin Monostory
Sep 1, 2015·Hepatology International·Amon AsgharpourArun Sanyal
Jul 2, 2015·Future Medicinal Chemistry·Valentina SepeAngela Zampella
Jun 21, 2013·Journal of Receptor and Signal Transduction Research·Vanesa StepanovMomir Mikov
Feb 25, 2015·Journal of Gastroenterology·Eleonora DistruttiStefano Fiorucci
Apr 20, 2016·Current Diabetes Reports·J David Mosinski, John P Kirwan
Nov 5, 2016·Progress in Lipid Research·Kim V E BraunOscar H Franco
Dec 3, 2016·Stem Cell Research & Therapy·Lulu FarhanaAdhip P N Majumdar

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Related Papers

American Journal of Physiology. Heart and Circulatory Physiology
Andrea MencarelliStefano Fiorucci
Proceedings of the National Academy of Sciences of the United States of America
J L StaudingerS A Kliewer
Journal of Cellular and Molecular Medicine
Andrea Mencarelli, Stefano Fiorucci
© 2022 Meta ULC. All rights reserved